NCT01872182TERMINATEDanonymous

A Randomized, Double-Blind, Placebo Controlled, Multicenter, 12-week Phase 3 Study to Evaluate Efficacy and Safety of ALS-L1023 Tablet in Patients With Abdominal Obesity of Metabolic Syndrome

Sponsor

Source record

Hanmi Pharmaceutical Company Limited

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

ALS-L1023, placebo

Indication / condition

AI-normalized

Abdominal Obesity Metabolic Syndrome

Intervention

Source record

ALS-L1023, placebo

Related intelligence directories

Indication directory: Abdominal Obesity Metabolic Syndrome Modality directory: small molecule Target directory: ALS-L1023

Source & freshness

Source record

NCT ID

NCT01872182

Original source

ClinicalTrials.gov

Source last updated

Oct 11, 2016

Ingested at

Jun 16, 2026

Internal sync

Jun 16, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT01872182

Title

A Randomized, Double-Blind, Placebo Controlled, Multicenter, 12-week Phase 3 Study to Evaluate Efficacy and Safety of ALS-L1023 Tablet in Patients With Abdominal Obesity of Metabolic Syndrome

Sponsor

Hanmi Pharmaceutical Company Limited

Status

TERMINATED

Phase

PHASE3

Condition raw

Abdominal Obesity Metabolic Syndrome

Condition normalized

Abdominal Obesity Metabolic Syndrome

Modality raw

small molecule

Modality normalized

small molecule

Target raw

ALS-L1023, placebo

Target normalized

ALS-L1023, placebo

Interventions

ALS-L1023, placebo

Public preview

Source record

The main objective of this study is to evaluate efficacy and safety of ALS-L1023 tablet in patients with abdominal obesity of metabolic syndrome.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Double-Blind, Placebo Controlled, Multicenter, 12-week Phase 3 Study to Evaluate Efficacy and Safety of ALS-L1023 Tablet in Patients With Abdominal Obesity of Metabolic Syndrome

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT01872182

Status

TERMINATED

Phase

PHASE3

Sponsor

Hanmi Pharmaceutical Company Limited

Executive brief

Investment-Ready Snapshot

The main objective of this study is to evaluate efficacy and safety of ALS-L1023 tablet in patients with abdominal obesity of metabolic syndrome.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedOct 11, 2016

Internal syncJun 16, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01872182

Indication

Abdominal Obesity Metabolic Syndrome

Modality

small molecule

Target

ALS-L1023, placebo

Intervention

ALS-L1023, placebo

Source record